Core Viewpoint - The company,拓新药业, is set to invest in a biomanufacturing base for raw materials and health dietary supplements in Inner Mongolia, with a total investment of 420 million yuan, aimed at enhancing production efficiency and market competitiveness [1] Investment Project Details - The investment agreement will be signed with the People's Government of Tokto County, Inner Mongolia [1] - The total investment for the project is 420 million yuan, with approximately 300 million yuan allocated for fixed asset investment [1] - The project aims to leverage the geographical advantages and resource endowments of Tokto County to establish a large-scale, standardized production base [1] Strategic Benefits - The investment will create favorable conditions for efficient research and production activities [1] - The abundant energy resources in the area are expected to help the company reduce production costs and expand profit margins [1] - Upon completion, the project will enhance the company's industrial chain layout, solidify its market position, and improve core profitability and sustainable development capabilities [1]
拓新药业(301089.SZ)：拟投建原料药及健康膳食补充剂生物制造基地建设项目